Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)
| Autor: | Curigliano, G., Murthy, R., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Cameron, D., Borges, V., Bedard, P., Oliveira, M., Jakobsen, E. H., Bachelot, T., Shachar, S. S., Mueller, V., Carey, L. A., Loibl, S., Feng, W., Walker, L. N., Winer, E. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Zdroj: | Curigliano, G, Murthy, R, Loi, S, Okines, A, Paplomata, E, Hamilton, E, Hurvitz, S A, Cameron, D, Borges, V, Bedard, P, Oliveira, M, Jakobsen, E H, Bachelot, T, Shachar, S S, Mueller, V, Carey, L A, Loibl, S, Feng, W, Walker, L N & Winer, E 2020, ' Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB) ', Annals of Oncology, vol. 31, no. Supplement 2, pp. S62-S63 . https://doi.org/10.1016/j.annonc.2020.03.238 |
| DOI: | 10.1016/j.annonc.2020.03.238 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|